Zika Vaccine: FDA grants Fast Track designation for Moderna’s mRNA-1893
by Press Release from Outbreak News Today on (#4NM7W)
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the ["]
The post Zika Vaccine: FDA grants Fast Track designation for Moderna's mRNA-1893 appeared first on Outbreak News Today.